Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00128167 | Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age | PHASE3 | COMPLETED | 8,500 | — | — | Oct 1, 2004 | Dec 1, 2005 | Sep 13, 2021 | 161 | United States, Belgium +6 |
| Name | Type | Description |
|---|---|---|
| Liquid CAIV-T | DRUG | - |
Inclusion Criteria: * Age 6-59 months of age (not yet reached their 5th birthday) * Parent or guardian available by telephone * Available for illness visits at clinic or at home during the influenza surveillance period * Written informed consent (and Health Insurance Portability and Accountability ...